67 related articles for article (PubMed ID: 22047736)
21. [The routine immunohistochemical diagnosis and surgical treatment of medullary carcinoma of the thyroid].
Gavrailov M; Petkov R; Mladenov B; Todorov G; Kŭtev N
Khirurgiia (Sofiia); 1995; 48(2):17-9. PubMed ID: 8531439
[TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity?
Holm R; Sobrinho-Simões M; Nesland JM; Sambade C; Johannessen JV
Lab Invest; 1987 Sep; 57(3):258-68. PubMed ID: 3626517
[TBL] [Abstract][Full Text] [Related]
23. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.
Scopsi L; Sampietro G; Boracchi P; Del Bo R; Gullo M; Placucci M; Pilotti S
Cancer; 1996 Nov; 78(10):2173-83. PubMed ID: 8918412
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic approach, genetic screening and prognostic factors of medullary thyroid carcinoma.
Corsello SM; Lovicu RM; Migneco MG; Rufini V; Summaria V
Rays; 2000; 25(2):257-66. PubMed ID: 11370543
[TBL] [Abstract][Full Text] [Related]
25. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma?
Cameselle-Teijeiro J; Chan JK
Mod Pathol; 1999 Apr; 12(4):400-11. PubMed ID: 10229505
[TBL] [Abstract][Full Text] [Related]
26. Sporadic medullary thyroid carcinoma associated with toxic multinodular goitre.
Small PK; Smith D
J R Coll Surg Edinb; 1997 Jun; 42(3):199-200. PubMed ID: 9195818
[TBL] [Abstract][Full Text] [Related]
27. Sustentacular cells occur frequently in the familial form of medullary thyroid carcinoma.
Matias-Guiu X; Machin P; Pons C; Lagarda E; De Leiva A; Prat J
J Pathol; 1998 Apr; 184(4):420-3. PubMed ID: 9664909
[TBL] [Abstract][Full Text] [Related]
28. [Incidence of familial non-medullary thyroid carcinoma in the patient register of the Clinic and Polyclinic of Nuclear Medicine, University of Würzburg].
Körber C; Geling M; Werner E; Mörtl M; Mäder U; Reiners C; Farahati J
Nuklearmedizin; 2000; 39(1):27-32. PubMed ID: 10726254
[TBL] [Abstract][Full Text] [Related]
29. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
30. [Medullary thyroid carcinoma--familial or sporadic disease?].
Høie J; Jørgensen OG; Nesland JM; Møller P; Bjøro K
Tidsskr Nor Laegeforen; 1994 Oct; 114(25):2951-4. PubMed ID: 7974404
[TBL] [Abstract][Full Text] [Related]
31. Familial nonmultiple endocrine neoplasia medullary thyroid carcinoma: an evolving clinical entity.
McHenry CR; Oppenheim DS; Murphy T; Broughan T; Vogt D; Goldfarb WB
Surgery; 1992 Oct; 112(4):728-32; discussion 732-3. PubMed ID: 1411944
[TBL] [Abstract][Full Text] [Related]
32. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
33. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.
Machens A; Hoffmann F; Sekulla C; Dralle H
Endocr Relat Cancer; 2009 Dec; 16(4):1291-8. PubMed ID: 19726541
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981.
Bergholm U; Adami HO; Bergström R; Johansson H; Lundell G; Telenius-Berg M; Akerström G
Cancer; 1989 Mar; 63(6):1196-204. PubMed ID: 2563669
[TBL] [Abstract][Full Text] [Related]
35. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
[TBL] [Abstract][Full Text] [Related]
36. [Histologic and immunohistochemical characterization of medullary thyroid carcinoma].
Abrosimov Aiu
Arkh Patol; 1996; 58(4):43-8. PubMed ID: 8967865
[TBL] [Abstract][Full Text] [Related]
37. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
38. Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma.
DeLellis RA; Wolfe HJ; Gagel RF; Feldman ZT; Miller HH; Gang DL; Reichlin S
Am J Pathol; 1976 Apr; 83(1):177-96. PubMed ID: 1275056
[TBL] [Abstract][Full Text] [Related]
39. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
40. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.
Uchino S; Noguchi S; Kawamoto H; Yamashita H; Watanabe S; Yamashita H; Shuto S
World J Surg; 2002 Aug; 26(8):897-902. PubMed ID: 11965446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
